Expert Overview from IAS 2011 [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 05 August 2011 00:00
- Written by Gregory Fowler
Cal Cohen from the Community Research Institute of New England provides an overview of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) recently held in Rome, including groundbreaking findings on treatment as prevention as well as data on experimental antiretroviral agents and new strategies for using existing drugs.
IAS 2011: HIV NNRTI Rilpivirine Effective and Well-Tolerated at 2 Years
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
The recently approved next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant) continued to show efficacy comparable to efavirenz (Sustiva) at 96 weeks, but with fewer central nervous system side effects and a more favorable lipid profile in the Phase 3 ECHO and THRIVE trials. 
IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.
IAS 2011: People with HIV Have Double Risk for Non-Melanoma Skin Cancers
- Details
- Category: Cancer/Malignancies
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
Several studies conducted in the era of effective antiretroviral therapy (ART) have shown that people with HIV have higher rates of non-AIDS-defining cancers, especially those caused by infectious pathogens such as human papillomavirus or hepatitis B or C.
IAS 2011: Final iPrEX Analysis Confirms PrEP Effectiveness for Gay Men
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 29 July 2011 00:00
- Written by Paul Dalton
Pre-exposure prophylaxis (PrEP) was shown to be highly effective for men and transgender women who have sex with men in a completed analysis of the large iPrEx trial presented at IAS 2011, but the prevention effect was blunted by low levels of adherence.
More Articles...
- IAS 2011: iPrEx Shows PrEP is Durable [VIDEO]
- IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated
- IAS 2011: Raltegravir Still Effective at 5 Years
- IAS 2011: Doubt Remains if HIV Therapy Increases the Risk of Fragility Fractures
- IAS 2011: HIV PrEP Effective for Heterosexuals, Discordant Couples
- IAS 2011: HIV Prevention -- A Women's Revolution [VIDEO]
- IAS 2011: New NNRTI Lersivirine Looks Good in Phase 2 Study
- IAS 2011: Cognitive Impairment is Common, but ART Reduces Risk
- HIV Drug Development News from IAS 2011 [VIDEO]
- IAS 2011: Randomized Trial Supports Earlier Treatment
Web Design and Development by